Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

NCT05807126 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

NIH

Sponsor class

Stopped No subjects enrolled in the study

Conditions

Anatomic Stage IV Breast Cancer AJCC v8
Castration-Resistant Prostate Carcinoma
Stage IVB Prostate Cancer AJCC v8

Interventions

PROCEDURE: Biopsy
PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
PROCEDURE: Magnetic Resonance Imaging
BIOLOGICAL: Magrolimab
DRUG: Olaparib

Sponsor

National Cancer Institute (NCI)